^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ARHGAP30 (Rho GTPase Activating Protein 30)

    i
    Other names: ARHGAP30, Rho GTPase Activating Protein 30, Rho-Type GTPase-Activating Protein 30, Rho GTPase-Activating Protein 30, FLJ00267
    Associations

    News

    Trials
    10d
    Immune Infiltration Landscape in Osteosarcoma: Clinical Implications for Prognosis and Therapy. (PubMed, Cancer Rep (Hoboken))
    This study highlights the prognostic and therapeutic relevance of immune infiltration in osteosarcoma. The ICI score and key genes offer insights into tumor heterogeneity and potential therapeutic targets, particularly in modulating macrophage polarization and enhancing antitumor immunity. Limitations include retrospective data and lack of functional validation. Future work should focus on experimental verification and clinical translation of these immune biomarkers.
    Journal
    |
    CD8 (cluster of differentiation 8) • ARHGAP30 (Rho GTPase Activating Protein 30)
    8ms
    Identification of clusters related to programmed cell death and potential prognostic biomarkers for immunotherapy response in endometrial cancer. (PubMed, Sci Rep)
    Conversely, patients with higher risk scores experienced poor clinical outcomes and reduced immunotherapy efficacy, although alternative therapies such as docetaxel and olaparib demonstrated potential therapeutic benefits. Overall, the RS provides a valuable tool for early prognosis prediction and for identifying patients who may benefit from immunotherapy.
    Journal • PARP Biomarker • IO biomarker
    |
    ARHGAP30 (Rho GTPase Activating Protein 30)
    |
    Lynparza (olaparib) • docetaxel
    over1year
    Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting. (PubMed, 3 Biotech)
    We investigated the potential of BTK as a tumor suppressor gene in predicting prolonged patient survival. In addition, we further investigated the possibility that BTK further affects the immunotherapeutic response of patients by influencing the microenvironment of tumor immune infiltration, but the relevant mechanisms remain to be further studied.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • BTK (Bruton Tyrosine Kinase) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • LPXN (Leupaxin) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15) • CD53 (CD53 Molecule) • ARHGAP30 (Rho GTPase Activating Protein 30)
    over1year
    A novel ARHGAP family gene signature for survival prediction in glioma patients. (PubMed, J Cell Mol Med)
    DCA analysis and cellular studies confirmed the model's potential to improve clinical treatment outcomes for patients. A novel ARHGAP family gene signature reveals the prognosis of glioma.
    Journal • Tumor mutational burden • Gene Signature
    |
    TMB (Tumor Mutational Burden) • ARHGAP • ARHGAP30 (Rho GTPase Activating Protein 30)
    almost2years
    KIAA1429 regulates lung adenocarcinoma proliferation and metastasis through the PI3K/AKT pathway by modulating ARHGAP30 expression. (PubMed, Thorac Cancer)
    This study revealed the activation mechanism and pivotal function of KIAA1429 in LUAD tumor development, paving the way for molecular-based interventions for LUAD.
    Journal
    |
    ARHGAP30 (Rho GTPase Activating Protein 30) • VIRMA (Vir Like M6A Methyltransferase Associated)
    almost2years
    Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer. (PubMed, Cancer Genomics Proteomics)
    Genes reported herein may be effective biomarkers to identify TNBC patients who will and will not benefit from immunotherapy and may be particularly important genes for developing future treatment strategies, including immunotherapy.
    Journal • IO biomarker • Immune cell
    |
    IFNG (Interferon, gamma) • CA9 (Carbonic anhydrase 9) • CD3D (CD3d Molecule) • ENO1 (Enolase 1) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • PRKCB (Protein Kinase C Beta) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand) • STAT4 (Signal Transducer And Activator Of Transcription 4) • ARHGAP30 (Rho GTPase Activating Protein 30)
    |
    CA9 expression
    over2years
    PABPC1 promotes cell proliferation and metastasis in pancreatic adenocarcinoma by regulating COL12A1 expression. (PubMed, Immun Inflamm Dis)
    The results of this study indicate that PABPC1 may function as a tumor promoter in PAAD, accelerating BXPC3 cell proliferation and metastasis by regulating COL12A1 expression.
    Journal
    |
    CAV1 (Caveolin 1) • AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding) • COL12A1 (Collagen Type XII Alpha 1 Chain) • PABPC1 (Poly(A) Binding Protein Cytoplasmic 1) • ARHGAP30 (Rho GTPase Activating Protein 30)